Literature DB >> 1581907

ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis.

K Sugio1, T Ishida, H Yokoyama, T Inoue, K Sugimachi, T Sasazuki.   

Abstract

Adenocarcinoma of the lung obtained at surgical resection was examined for mutation at codons 12, 13, and 61 of the oncogenes K-ras, H-ras, and N-ras, using polymerase chain reaction and oligonucleotide hybridization techniques. The mutation was detected in 18 of the 115 cases (15.7%), and 15 of 18 were at codon 12, 2 were at codon 13 of K-ras, and 1 was at codon 61 of N-ras. G to T transversions were most common. The ras gene mutations were more frequent in the male patients (P = 0.0048). No significant differences were found to be related to stage of the disease or tumor-nodes-metastases classification between positive and negative groups of the ras gene mutations. A history of tobacco use was not always a factor contributing to mutation. Of the completely resected group without lymph node metastasis, the 5-year survival rate in the ras-positive group was 53.3%, which was significantly poorer than the 83.6% survival rate in the ras-negative group (P less than 0.05). Our findings suggest that ras gene mutations may be prognostic, especially in the early stage adenocarcinoma of the lung.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1581907

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  Detection of micrometastatic tumor cells in pN0 lymph nodes of patients with completely resected nonsmall cell lung cancer: impact on recurrence and Survival.

Authors:  Chun-Dong Gu; Toshihiro Osaki; Tsunehiro Oyama; Masaaki Inoue; Mantaro Kodate; Kazuhito Dobashi; Takeshi Oka; Kosei Yasumoto
Journal:  Ann Surg       Date:  2002-01       Impact factor: 12.969

Review 2.  New prognostic factors in resectable non-small cell lung cancer.

Authors:  E F Smit; H J Groen; T A Splinter; T Ebels; P E Postmus
Journal:  Thorax       Date:  1996-06       Impact factor: 9.139

3.  Expression of oncoproteins in primary human non-small cell lung cancer and incidence of metastases.

Authors:  M Volm; P Drings; W Wodrich; G van Kaick
Journal:  Clin Exp Metastasis       Date:  1993-07       Impact factor: 5.150

4.  Mutations of the EGFR, K-ras, EML4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma.

Authors:  Taro Ohba; Gouji Toyokawa; Atsushi Osoegawa; Fumihiko Hirai; Masafumi Yamaguchi; Ken-Ichi Taguchi; Takashi Seto; Mitsuhiro Takenoyama; Yukito Ichinose; Kenji Sugio
Journal:  Surg Today       Date:  2015-12-28       Impact factor: 2.549

5.  TPL2 kinase is a suppressor of lung carcinogenesis.

Authors:  Katerina Gkirtzimanaki; Kalliopi K Gkouskou; Urszula Oleksiewicz; Georgios Nikolaidis; Dimitra Vyrla; Michalis Liontos; Vassiliki Pelekanou; Dimitris C Kanellis; Kostantinos Evangelou; Efstathios N Stathopoulos; John K Field; Philip N Tsichlis; Vassilis Gorgoulis; Triantafillos Liloglou; Aristides G Eliopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-26       Impact factor: 11.205

6.  K-ras gene mutations: an unfavorable prognostic marker in stage I lung adenocarcinoma.

Authors:  E M Silini; F Bosi; N S Pellegata; G Volpato; A Romano; S Nazari; C Tinelli; G N Ranzani; E Solcia; R Fiocca
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

7.  Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients.

Authors:  M I Galleges Ruiz; K Floor; S M Steinberg; K Grünberg; F B J M Thunnissen; J A M Belien; G A Meijer; G J Peters; E F Smit; J A Rodriguez; G Giaccone
Journal:  Br J Cancer       Date:  2008-12-02       Impact factor: 7.640

8.  High K-ras mutation rates in goblet-cell-type adenocarcinomas of the lungs.

Authors:  E Tsuchiya; R Furuta; N Wada; K Nakagawa; Y Ishikawa; B Kawabuchi; Y Nakamura; H Sugano
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

9.  Mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance.

Authors:  Taro Ohba; Gouji Toyokawa; Takuro Kometani; Kaname Nosaki; Fumihiko Hirai; Masafumi Yamaguchi; Motoharu Hamatake; Takashi Seto; Yukito Ichinose; Kenji Sugio
Journal:  Surg Today       Date:  2013-04-23       Impact factor: 2.549

10.  c-k-ras and p53 mutations occur very early in adenocarcinoma of the lung.

Authors:  Z H Li; J Zheng; L M Weiss; D Shibata
Journal:  Am J Pathol       Date:  1994-02       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.